Northwest Biotherapeutics, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY1998 | 51.2% | 51.2% | — |
| FY1999 | 37.9% | 37.9% | — |
| FY2000 | 56.8% | 56.8% | — |
| FY2001 | -64.6% | -64.6% | — |
| FY2002 | -262.6% | -262.6% | — |
| FY2003 | -38,346.7% | -38,346.7% | — |
| FY2004 | 163.1% | 163.1% | — |
| FY2005 | 87.0% | 87.0% | — |
| FY2006 | 23.4% | 23.4% | — |
| FY2007 | -365.9% | -365.9% | — |
| FY2008 | 181.6% | 181.6% | — |
| FY2009 | 130.3% | 130.3% | — |
| FY2010 | 98.9% | 98.9% | -9,308.8% |
| FY2011 | 62.9% | 62.9% | -15,485.8% |
| FY2012 | 418.8% | 418.8% | -889.3% |
| FY2013 | 670.1% | 670.1% | -350.2% |
| FY2014 | 387.2% | 387.2% | -240.2% |
| FY2015 | 2,453.8% | -632.9% | -162.1% |
| FY2016 | 302.7% | -1,539.0% | -151.6% |
| FY2017 | 108.6% | 203.7% | -149.6% |
| FY2018 | 74.4% | 114.2% | -145.1% |
| FY2019 | 46.2% | 64.4% | -195.5% |
| FY2020 | 146.0% | 152.2% | -1,610.4% |
| FY2021 | -144.5% | -195.6% | 446.0% |
| FY2022 | 82.0% | 98.6% | -335.3% |
| FY2023 | 95.2% | 250.6% | -224.7% |
| FY2024 | 88.7% | 263.4% | -313.4% |
| FY2025 | 99.8% | 25,278.2% | -74.0% |